Decoy Therapeutics Inc. DCOY
Pharmaceutical Preparations · CIK 0001615219 · Fiscal year ends 1231
Revenue
$227.63K
Fiscal year ended 2026-06-30Operating income
-$2.63M
Fiscal year ended 2026-06-30Free cash flow
—Unavailable
Fiscal year ended 2026-06-30Valuation, from the filing
| Public float | $1.90M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
Decoy Therapeutics Inc. (DCOY) reported revenue of $227.63K and net income of -$2.37M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Decoy Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
Decoy Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-06-30 | 2025-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|
| Revenue | $227.63K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $571.39K |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$2.63M | -$965.56K | -$5.42M | -$6.48M | -$14.49M | -$4.76M | -$6.12M | -$4.14M | -$3.75M | -$3.12M |
|---|
| Net income | -$2.37M | -$957.82K | -$5.34M | -$6.37M | -$14.41M | -$4.72M | -$6.11M | -$4.10M | -$3.74M | -$3.07M |
|---|
| Research & development | $1.30M | $116.38K | $3.73M | $4.69M | $3.79M | $2.92M | $4.44M | $2.70M | $2.02M | $2.10M |
|---|
| Weighted-average diluted shares | —Unavailable | —Unavailable | shares 2.39M | —Unavailable | shares 2.25M | shares 2.14M | shares 1.85M | —Unavailable | shares 1.79M | shares 44.76M |
|---|
| Pretax income | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Income tax expense | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Diluted EPS | $-4.46 | $-81.21 | $-2.23 | —Unavailable | $-6.41 | $-2.20 | $-3.30 | —Unavailable | $-2.09 | $-0.07 |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| General & administrative | $1.33M | $849.18K | $1.70M | $1.79M | $1.83M | $1.84M | $1.68M | $1.45M | $1.73M | $1.59M |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
Decoy Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-06-30 | 2025-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|
| Cash & equivalents | $8.29M | $794.89K | $9.27M | $12.11M | $16.82M | $22.65M | $24.19M | $29.21M | $31.90M | $33.08M |
|---|
| Total assets | $9.00M | $1.39M | $10.06M | $14.65M | $19.72M | $33.65M | $35.51M | $40.83M | $44.26M | $47.40M |
|---|
| Current assets | $8.57M | $1.36M | $9.94M | $14.52M | $17.97M | $23.02M | $24.86M | $30.16M | $35.18M | $38.31M |
|---|
| Total liabilities | $4.68M | $2.22M | $4.50M | $4.27M | $3.11M | $2.77M | $2.09M | $2.11M | $1.61M | $1.55M |
|---|
| Current liabilities | $4.68M | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Total equity incl. NCI | $4.32M | -$829.72K | $5.56M | $10.38M | $16.61M | $30.88M | $33.42M | $38.72M | $42.65M | $45.85M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $1.60M | $1.60M | $1.60M | $1.60M | $2.09M | $4.79M |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | $0 | $0 | $8.87M | $8.87M | $8.87M | $8.87M | $8.87M |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts payable | $1.33M | $1.48M | $3.51M | $2.86M | $1.72M | $1.87M | $1.69M | $1.54M | $1.23M | $1.28M |
|---|
Cash flow
Decoy Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-06-30 | 2025-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|
| Operating cash flow | —Unavailable | —Unavailable | -$3.17M | -$4.71M | -$5.74M | -$3.62M | -$3.52M | -$2.72M | -$1.58M | -$3.17M |
|---|
| Capital expenditures | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Investing cash flow | —Unavailable | —Unavailable | $0 | $0 | $0 | $0 | -$1.50M | $0 | $0 | $0 |
|---|
| Financing cash flow | —Unavailable | —Unavailable | $336.68K | $1 | -$85.70K | $2.07M | $0 | $31.26K | $406.36K | -$358.12K |
|---|
| Net change in cash | —Unavailable | —Unavailable | -$2.83M | -$4.71M | -$5.83M | -$1.55M | -$5.02M | -$2.69M | -$1.18M | -$3.53M |
|---|
| Stock-based compensation | —Unavailable | —Unavailable | $203.34K | $145.51K | $137.86K | $199.53K | $313.90K | $145.89K | $130.32K | $147.46K |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | —Unavailable | $1.67K | $1.67K | $1.67K | -$1.46K | $4.80K | $4.80K | $4.80K | $4.80K |
|---|
Derived
Decoy Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-06-30 | 2025-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|
| Free cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | -1155.8% | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -545.5% |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | 25.8% |
|---|
| Current ratio | 1.83x | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Revenue YoY growth | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -100.0% | -100.0% | -100.0% | -100.0% | -54.0% |
|---|
| Net margin | -1042.8% | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| R&D / revenue | 573.0% | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | 366.9% |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DCOY in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.